Tuberculosis Clinical Trial
— CL-004Official title:
A Phase 1, Open-Label, Single-Dose Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of [14C]-PA 824 in Healthy Adult Male Subjects.
NCT number | NCT03202693 |
Other study ID # | PA 824-CL-004 |
Secondary ID | |
Status | Completed |
Phase | Phase 1 |
First received | |
Last updated | |
Start date | March 2006 |
Est. completion date | May 2006 |
Verified date | February 2018 |
Source | Global Alliance for TB Drug Development |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is a Phase 1, single-center, open-label, single-dose study to evaluate (1) the absorption, metabolism, and excretion patterns of a single dose of [14C] PA-824, and (2) the pharmacokinetics, safety, and tolerability of a single oral-suspension dose of unlabeled PA-824 in healthy adult male subjects. Unlabeled PA-824 and [14C]-PA-824 will be administered together in an oral-suspension formulation. Enrollment is planned for one dose group of 6 subjects. All 6 subjects will receive the same treatment.
Status | Completed |
Enrollment | 6 |
Est. completion date | May 2006 |
Est. primary completion date | May 2006 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 19 Years to 50 Years |
Eligibility |
Inclusion Criteria: 1. Be healthy non-tobacco/nicotine using (6-month minimum) adult male subjects, 19 to 50 years of age, inclusive 2. Weigh within 20% of their ideal weights (Table of "Desirable Weights of Adults", Metropolitan Life Insurance Company, 1999) 3. Be medically healthy subjects with clinically insignificant Screening results (among laboratory profiles, medical histories, ECGs, or physical exam), as deemed by the Principal Investigator in consultation with the Sponsor Medical Monitor. 4. Have a history of regular bowel movements (5-6 movements week, ideally 1 per day), as deemed by the Principal Investigator in consultation with the Sponsor Medical Monitor. 5. Have negative urinalysis test results for drugs of abuse such as amphetamines, cannabinoids, and cocaine metabolites 6. Have the ability to understand the requirements of the study, have provided written informed consent (as evidenced by signature on an informed consent document approved by an IRB), and agree to abide by the study restrictions Exclusion Criteria: 1. Any acute illness or history or presence of significant (as deemed by the Principal Investigator) cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease 2. Any preexisting condition that would interfere with normal anatomy or function of the gastrointestinal tract. 3. Any medical condition that would interfere with radiocarbon assessments. 4. Any serum creatinine or BUN measure beyond the upper limit of the normal range at Screening or Check-in. 5. Positive Screening test for HCV, HBV, or HIV 6. History of peptic ulcer disease, gastritis, esophagitis, or gastroesophageal reflux disease 7. History of any cardiac abnormality (as deemed by the Principal Investigator) 8. History of hypokalemia or hypomagnesemia 9. History of prolonged QT interval 10. Family history of Long-QT Syndrome or sudden death 11. Resting pulse rate < 40 or > 100 bpm at both Screening and Check-in 12. QTc interval > 430 msec as documented at Screening and Baseline (Check-in) ECG 13. History or presence of alcoholism or drug abuse within the past year (as deemed by the Principal Investigator) 14. Use of alcohol within 72 hours prior to dosing 15. Significant history of drug and/or food allergies (as deemed by the Principal Investigator) 16. Use of any prescription medication within 14 days prior to dosing or during the study 17. Use of any over-the-counter medication including vitamins, herbal preparations, antacids, cough and cold remedies, etc., within 7 days prior to dosing or during the study 18. Use of any drugs or substances within 30 days prior to dosing known to be strong inhibitors or inducers of cytochrome P450 enzymes or known to prolong the QT interval 19. Consumption of products containing grapefruit within 10 days prior to dosing 20. Any special dietary changes during the 30 days prior to dosing, as deemed by the Principal Investigator in consultation with the Sponsor Medical Monitor 21. Any strenuous exercise within 1 week of Check-in, as deemed by the Principal Investigator in consultation with the Sponsor Medical Monitor 22. Known allergies to Na CMC or DMSO, components of the formulation to be used in this study 23. Current employment in a job requiring radiation-exposure monitoring 24. Participation in any study involving radioactivity within the last 12 months 25. More than one X-ray greater than the equivalent of one routine chest X-ray or one routine dental X-ray in the past 12 months 26. Donation of whole blood within 56 days prior to dosing 27. Plasma donation within 7 days prior to dosing 28. Participation in another clinical trial within 30 days prior to dosing 29. Hemoglobin < 12.0 g/dL 30. Previous use of PA-824 |
Country | Name | City | State |
---|---|---|---|
United States | Covance Clinical Research Unit | Madison | Wisconsin |
Lead Sponsor | Collaborator |
---|---|
Global Alliance for TB Drug Development |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Characterize the plasma pharmacokinetic variable area under the curve of a single oral-suspension dose of PA-824. | Characterize the plasma pharmacokinetics of a single oral-suspension dose of PA-824 in healthy adult male subjects by calculating the variable area under the curve [AUC (0-t)] from total PA-824 plasma concentrations. | Days 0-12 | |
Primary | Characterize the plasma pharmacokinetic variable maximum concentration of a single oral-suspension dose of PA-824. | Characterize the plasma pharmacokinetics of a single oral-suspension dose of PA-824 in healthy adult male subjects by calculating the variable maximum plasma concentration (Cmax) from total PA-824 plasma concentrations. | Days 0-12 | |
Primary | Characterize the plasma pharmacokinetic variable time to peak plasma concentration of a single oral-suspension dose of PA-824. | Characterize the plasma pharmacokinetics of a single oral-suspension dose of PA-824 in healthy adult male subjects by calculating the variable time to peak plasma concentration (Tmax) from total PA-824 plasma concentrations. | Days 0-12 | |
Secondary | The frequency and severity of treatment related adverse events throughout the study. | In order to evaluate the safety and tolerability of a single oral-suspension dose of PA-824 in healthy adult male subjects | Days 0 -12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |